Welcome to our dedicated page for Cbdmd SEC filings (Ticker: YCBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
cbdMD, Inc. filings document a North Carolina cannabinoid-products company with disclosures covering securities registration, capital structure, governance and material agreements.
The record includes Securities Act registration statements, proxy disclosures on executive compensation and shareholder matters, and 8-K reports on director equity compensation, board fees, operating and financial results, and the completed Bluebird Botanicals asset purchase, including acquired brand, online marketplace, trademarks, inventory and share-based consideration.
cbdMD, Inc. reported a new executive employment agreement and a fresh equity compensation plan. The company entered into a three-year agreement with CEO and CFO T. Ronan Kennedy, providing a base salary of $340,000 and a restricted stock award covering 445,000 shares of common stock under the new 2025 Equity Compensation Plan. Vesting and issuance of these shares are subject to shareholder approval.
The board approved the 2025 Equity Compensation Plan, which reserves 891,316 shares of common stock for options, restricted stock, and other stock-based awards. The plan includes an “evergreen” feature that can automatically increase the share pool annually based on a percentage of shares outstanding, subject to caps. Awards may be granted to employees, officers, directors, and consultants and are administered by the board’s Compensation, Corporate Governance and Nominating Committee. Grants under the plan will not vest until shareholders approve it, and incentive stock option treatment depends on that approval.
cbdMD, Inc. filed a Form 8-K to report that on November 21, 2025 it issued a press release announcing preliminary net revenues for its fourth quarter and fiscal year ended September 30, 2025, along with certain other operating data for those periods. The press release is included as Exhibit 99.1.
The company states that this information is being furnished, not filed, under the securities laws, which means it is not subject to certain liability provisions and is not automatically incorporated into other cbdMD, Inc. filings.
cbdMD, Inc. filed an S-1 registering the potential resale of up to 1,700,000 shares of common stock by selling shareholders. The registered shares are issuable upon conversion of Series B Convertible Preferred Stock sold on September 29, 2025 pursuant to Purchase Agreements. cbdMD will not receive proceeds from any resale of these shares.
The Series B Preferred is convertible at $1.00 per share, subject to anti‑dilution adjustments and a floor conversion price of $0.50 per share, and accrues dividends at 10% per annum, payable in cash or stock subject to equity conditions. A 4.99% beneficial ownership limitation applies to conversions. An exchange cap limits issuances without prior shareholder approval to 19.99% of pre‑transaction outstanding shares, identified as 1,782,518 shares.
Shares outstanding were 8,919,410 as of November 6, 2025. The company states 10,619,410 shares outstanding assuming full conversion at a $1.00 conversion price. cbdMD previously received $1,700,000 gross proceeds from the private placement of the Series B Preferred for working capital and general corporate purposes.
cbdMD, Inc. issued 1,700,000 shares of newly designated Series B Convertible Preferred Stock to four institutional investors for aggregate gross proceeds of $1,700,000 and net proceeds of $1,500,000, to be used for working capital. Each preferred share converts into common stock at a conversion price of $1.00 subject to anti-dilution and special conversion rights. The Series B accrues dividends at 10% per annum payable quarterly in common shares or cash subject to defined equity conditions; unpaid dividends may increase the stated value if cash payment is restricted by North Carolina law. The preferred ranks senior on liquidation, carries no voting rights except as required by law, and includes a 4.99% beneficial ownership cap on conversion. The company agreed to file a registration statement for the underlying common shares within 30 days of closing per registration rights agreements.